FORMULATION, OPTIMIZATION AND CHARACTERIZATION SOLID LIPID NANOPARTICLES OF CABAZITAXEL
Keywords:
Tumor, Solid Lipid Nanoparticles (SLNs), Cabazitaxel(CTX), Tristearin, StearylamineAbstract
Tumors are characterized by poorly differentiated, highly chaotic arrangement of vessels which have unsealed endothelial cell–cell, junctions and discontinuous basement membrane. These are characterized by interstitial hypertension, low extracellular pH, hypoxia, angiogenesis, tumor– stromal cell interaction, cancer stem cells, and abnormal lymphatics and key microenvironmental features of solid tumors greatly impact the extravasation of polymeric nanomedicines like solid lipid nanoparticles (SLNs). Solid Lipid Nanoparticles (SLNs) are rapidly developing field of nanotechnology is one of the approaches to improve bioavailability by targeting the antineoplastic drug Cabazitaxel (CTX) to the tumor. The present research work is to formulate and optimize the Cabazitaxel SLNs by simple solvent injection method. Solid Lipid Nanoparticles (SLNs) of Cabazitaxel were formulated by taking Tristearin and Stearylamine as lipid matrix, Tween 80 as surfactant and soya lecithin as co emulsifier. Sonication and stirring were important process to optimize the size of Solid Lipid Nanoparticles. The optimization was carried out of various variables on the basis of particle size, shape, and polydispersity index and drug entrapment efficiency. Solid Lipid Nanoparticles (SLNs) of Cabazitaxel optimized with Tristearin and Stearylamine ratio (1.5:1.0), drug lipid ratio(1:10) with 1% of Tween80, stirring at speed about 3000 for 60 minutes and 2 minutes of sonication for minimum size. The optimized Formulation of SLN showed a % cumulative drug release of 79.94±1.88% up to 48 hours in PBS (pH 7.4).
References
1.Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol,
2.2010; 7: 653–664.
3.Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci., 2003; 94: 15–21.
4.Cortesi R., Esposito E., Luca G., Nastruzzi C., Production of lipospheres as carriers for bioactive compounds, Biomaterials, 2000; 23: 2283-94.
5.Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 2005; 5: 161–171.
6.Neerman MF Enhancing the site specific targeting of macromolecular anti-cancer drug delivery system. Curr Drug Targets, 2006; 7: 229-235.
7.Pandey R., Sharma S., Khuller GK., Oral SLN Based antitubercular chemotherapy,
8.Tuberculosis (Edinb), 2005; 85: 415-20.
9.Wani M, Taylor H, Wall M, Coggon P, McPhail A. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc., 1971; 93(9): 2325–2327.
10.Hu F. Q., Zhang Y., Du Y. Z., Yuan, H., Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system, Int J Pharm., 2008; 348: 146–52.
11.Jain NK Advances in Controlled and Novel Drug Delivery. CBS Publishers and Distributors, New Delhi, 1st ed., 2001; 40-69.
12.Ler R., Manger W., Scouloudis M., Ku A., Davis C., Lee A., Solid Lipid Nanoparticles: A review Biotech. Progress, 2000; 16: 80-85.
13.Prashant Kesarwani, Rakesh K. Tekade, N. K. Jain Spectrophotometric estimation of cabazitaxel. International Journal of Advances in Pharmaceutical Sciences, 2011; 2: 29-32.
14.Santos M.C., Mehnert W., Schaller M., Drug targeting by solid lipid nanoparticles for dermal use, J Drug Target, 2002; 10: 489-95.
